Stocksigma LogoStocksigma Logo

AstraZeneca Pharma India Reports 30% Revenue Growth in Q2 FY'26-27

AstraZeneca Pharma India reported a 30% YoY rise in revenue from operations for Q2 FY'26-27 (Jul'26鈥揝ep'26) at INR 7,291 Mn, up from INR 5,591 Mn

AstraZeneca Pharma India Reports 30% Revenue Growth in Q2 FY'26-27

AstraZeneca Pharma India Ltd 路 Press Release 路 06 Nov 2026, 1:04 am

AstraZeneca Pharma India Reports 30% Revenue Growth in Q2 FY'26-27 AstraZeneca Pharma India reported a 30% YoY rise in revenue from operations for Q2 FY'26-27 (Jul'26鈥揝ep'26) at INR 7,291 Mn, up from INR 5,591 Mn. H1 FY'26-27 revenue also surged 30% YoY to INR 14,119 Mn. Growth was led by Oncology at INR 5,085 Mn (vs. INR 3,978 Mn), Biopharmaceuticals at INR 1,610 Mn (vs. INR 1,268 Mn), and Rare Diseases at INR 204 Mn (vs. INR 38 Mn). The company secured key regulatory approvals for Trastuzumab deruxtecan, Benralizumab, and Acalabrutinib combinations.

Original exchange filing (PDF)

More announcements from AstraZeneca Pharma India Ltd

All AstraZeneca Pharma India Ltd announcements